首页> 外文期刊>The Journal of Pathology: Clinical Research >Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett's oesophagus
【24h】

Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett's oesophagus

机译:多基因下一代测序专家组在无创食管细胞采样设备中诊断增生性巴雷特食管的应用

获取原文
           

摘要

Abstract The early detection and endoscopic treatment of patients with the dysplastic stage of Barrett's oesophagus is a key to preventing progression to oesophageal adenocarcinoma. However, endoscopic surveillance protocols are hampered by the invasiveness of repeat endoscopy, sampling bias, and a subjective histopathological diagnosis of dysplasia. In this case-control study, we investigated the use of a non-invasive, pan-oesophageal cell-sampling device, the Cytosponge?¢???¢, coupled with a cancer hot-spot panel to identify patients with dysplastic Barrett's oesophagus. Formalin-fixed, paraffin-embedded (FFPE) Cytosponge?¢???¢ samples from 31 patients with non-dysplastic and 28 with dysplastic Barrett's oesophagus with good available clinical annotation were selected for inclusion. Samples were microdissected and amplicon sequencing performed using a panel covering > 2800 COSMIC hot-spot mutations in 50 oncogenes and tumour suppressor genes . S trict mutation criteria were determined and duplicates were run to confirm any mutations with an allele frequency <12%. When compared with endoscopy and biopsy as the gold standard the panel achieved a 71.4% sensitivity (95% CI 51.3?¢????86.8) and 90.3% (95% CI 74.3?¢????98.0) specificity for diagnosing dysplasia. TP53 had the highest rate of mutation in 14/28 dysplastic samples (50%). CDKN2A was mutated in 6/28 (21.4%), ERBB2 in 3/28 (10.7%), and 5 other genes at lower frequency. The only gene from this panel found to be mutated in the non-dysplastic cases was CDKN2A in 3/31 cases (9.7%) in keeping with its known loss early in the natural history of the disease. Hence, it is possible to apply a multi-gene cancer hot-spot panel and next-generation sequencing to microdissected, FFPE samples collected by the Cytosponge?¢???¢, in order to distinguish non-dysplastic from dysplastic Barrett's oesophagus. Further work is required to maximize the panel sensitivity.
机译:摘要对Barrett食管增生异常患者的早期发现和内窥镜治疗是防止其发展为食道腺癌的关键。然而,内窥镜监测方案受到重复内窥镜检查的侵袭性,取样偏差以及对发育异常的主观组织病理学诊断的阻碍。在这项病例对照研究中,我们调查了无创,全食道细胞采样设备Cytosponge?¢ ??????以及癌症热点小组的使用,以识别发育不良的Barrett食道患者。选择福尔马林固定,石蜡包埋(FFPE)的细胞海绵体样本,这些样本来自31例非发育异常的患者和28例发育不良的Barrett食道患者,并具有良好的临床注释。使用覆盖50个癌基因和肿瘤抑制基因中的> 2800个COSMIC热点突变的面板对样品进行显微解剖并进行扩增子测序。确定了S trict突变标准,并进行重复实验以确认等位基因频率<12%的任何突变。当与内镜和活检作为金标准进行比较时,该小组在诊断异常增生方面达到了71.4%的敏感性(95%CI 51.3-86.8)和90.3%(95%CI 74.3 -98.0)特异性。 。 TP53在14/28增生异常样品中的突变率最高(50%)。 CDKN2A在6/28(21.4%)中突变,ERBB2在3/28(10.7%)中突变,而其他5个基因的突变频率较低。在非增生性病例中,该组中唯一被突变的基因是3/31例中的CDKN2A(9.7%),与该疾病自然史早期已知的丢失保持一致。因此,有可能将多基因癌症热点研究小组和下一代测序技术应用于通过细胞海绵收集的显微解剖的FFPE样品,以区分发育不良的巴雷特食管和发育不良的食管。需要进一步的工作以最大化面板灵敏度。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号